Thursday's HotCopper trends: Telix FDA issue, Burkina-Faso WAF acquisition | Aug 28


With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets – which is why getting out in front of those trends is so important for any trader worth their salt.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

In this daily HotCopper Trends column, we break down the top three stocks talked about on any given trade day, and why they’ve drawn a daily focus.

Topping the forum talks today is Telix Pharmaceuticals (ASX:TLX). The Australian biopharma company has been followed for a while on HotCopper boards; it’s today drawing ire after plunging -17% on a U.S. regulatory setback.

I’ll let my colleague Jonathan Davidson describe it in more detail here, but basically, the FDA hasn’t let its latest Biologics License Application through.

Also trending today is West African Resources (ASX:WAF), after the Oz explorer halted to prepare for a request from the Burkina Faso government to acquire for “valuable paid consideration” another 35% in Kiaka SA.

And, Lynas Rare Earths (ASX:LYC) has been drawing a whole lot of discussion – and positive sentiments to boot – after unveiling plans to raise more than $800 million to fund its non-China critical minerals push.

LYC has been paused since 8.40am. It was last $14.73/sh.

As for the ASX, it’s been a mixed day; at time of writing, it’s up +0.1%.

That’s Thursday’s HotCopper Market Trends, I’m Isaac McIntyre – see you for close.

Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.


arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.